Home > News > BioSante Pharmaceuticals Announces Positive Results
April 29th, 2004
BioSante Pharmaceuticals Announces Positive Results
BioSante Pharmaceuticals, Inc. today announced that a comparative preclinical study demonstrated its calcium phosphate nanotechnology-based vaccine adjuvant, BioVant(TM), may be more effective than aluminum salt derivatives, the only adjuvant currently approved by the Food and Drug Administration. The study was conducted in collaboration with the U.S. Centers for Disease Control and Prevention in a previously unannounced BioSante collaboration.
Newly-Developed Nanobiosensor Quickly Diagnoses Cancer August 20th, 2014
Graphene rubber bands could stretch limits of current healthcare, new research finds August 19th, 2014
Interaction between Drug, DNA for Designing Anticancer Drugs Studied in Iran August 17th, 2014
Iranian Scientists Stabilize Protein on Highly Stable Electrode Surface August 14th, 2014